Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis

Navdeep Tangri, Morgan E Grams, Andrew S Levey, Josef Coresh, Lawrence J Appel, Brad C Astor, Gabriel Chodick, Allan J Collins, Ognjenka Djurdjev, C Raina Elley, Marie Evans, Amit X Garg, Stein I Hallan, Lesley A Inker, Sadayoshi Ito, Sun Ha Jee, Csaba P Kovesdy, Florian Kronenberg, Hiddo J Lambers Heerspink, Angharad Marks, Girish N Nadkarni, Sankar D Navaneethan, Robert G Nelson, Stephanie Titze, Mark J Sarnak, Benedicte Stengel, Mark Woodward, Kunitoshi Iseki, CKD Prognosis Consortium, Jackson T Wright Jr, Lawrence J Appel, Tom Greene, Brad C Astor, Josef Coresh, Kunihiro Matsushita, Morgan E Grams, Yingying Sang, Adeera Levin, Ognjenka Djurdjev, Sankar D Navaneethan, Joseph V Nally Jr, Jesse D Schold, David C Wheeler, Jonathan Emberson, Jonathan N Townend, Martin J Landray, Lawrence J Appel, Harold Feldman, Chi-yuan Hsu, Kai-Uwe Eckardt, Anna Kottgen, Florian Kronenberg, Stephanie Titze, Jamie Green, H Lester Kirchner, Robert Perkins, Alex R Chang, Corri Black, Angharad Marks, Nick Fluck, Laura Clark, Gordon J Prescott, Sadayoshi Ito, Mariko Miyazaki, Masaaki Nakayama, Gen Yamada, Stein Hallan, Knut Aasarød, Solfrid Romundstad, David H Smith, Micah L Thorp, Eric S Johnson, Allan J Collins, Shu-Cheng Chen, Suying Li, Gabriel Chodick, Varda Shalev, Nachman Ash, Bracha Shainberg, Jack F M Wetzels, Peter J Blankestijn, Arjan D van Zuilen, Mark J Sarnak, Andrew S Levey, Lesley A Inker, Vandana Menon, Florian Kronenberg, Barbara Kollerits, Eberhard Ritz, Girish N Nadkarni, Erwin P Bottinger, Stephen B Ellis, Rajiv Nadukuru, Marc Froissart, Benedicte Stengel, Marie Metzger, Jean-Philippe Haymann, Pascal Houillier, Martin Flamant, C Raina Elley, Timothy Kenealy, Simon A Moyes, John F Collins, Paul L Drury, Kunitoshi Iseki, Amit X Garg, Eric McArthur, Gihad Nesrallah, S Joseph Kim, Robert G Nelson, William C Knowler, David G Warnock, Paul Muntner, Suzanne Judd, William McClellan, Orlando Gutierrez, Hiddo J Lambers Heerspink, Barry E Brenner, Dick de Zeeuw, Sun Ha Jee, Heejin Kimm, Yejin Mok, Marie Evans, Maria Stendahl, Navdeep Tangri, Maneesh Sud, David Naimark, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Josef Coresh, Ron T Gansevoort, Morgan E Grams, Paul E de Jong, Kunitoshi Iseki, Andrew S Levey, Kunihiro Matsushita, Mark J Sarnak, Benedicte Stengel, David Warnock, Mark Woodward, Shoshana H Ballew, Josef Coresh, Morgan E Grams, Kunihiro Matsushita, Yingying Sang, Mark Woodward, Navdeep Tangri, Morgan E Grams, Andrew S Levey, Josef Coresh, Lawrence J Appel, Brad C Astor, Gabriel Chodick, Allan J Collins, Ognjenka Djurdjev, C Raina Elley, Marie Evans, Amit X Garg, Stein I Hallan, Lesley A Inker, Sadayoshi Ito, Sun Ha Jee, Csaba P Kovesdy, Florian Kronenberg, Hiddo J Lambers Heerspink, Angharad Marks, Girish N Nadkarni, Sankar D Navaneethan, Robert G Nelson, Stephanie Titze, Mark J Sarnak, Benedicte Stengel, Mark Woodward, Kunitoshi Iseki, CKD Prognosis Consortium, Jackson T Wright Jr, Lawrence J Appel, Tom Greene, Brad C Astor, Josef Coresh, Kunihiro Matsushita, Morgan E Grams, Yingying Sang, Adeera Levin, Ognjenka Djurdjev, Sankar D Navaneethan, Joseph V Nally Jr, Jesse D Schold, David C Wheeler, Jonathan Emberson, Jonathan N Townend, Martin J Landray, Lawrence J Appel, Harold Feldman, Chi-yuan Hsu, Kai-Uwe Eckardt, Anna Kottgen, Florian Kronenberg, Stephanie Titze, Jamie Green, H Lester Kirchner, Robert Perkins, Alex R Chang, Corri Black, Angharad Marks, Nick Fluck, Laura Clark, Gordon J Prescott, Sadayoshi Ito, Mariko Miyazaki, Masaaki Nakayama, Gen Yamada, Stein Hallan, Knut Aasarød, Solfrid Romundstad, David H Smith, Micah L Thorp, Eric S Johnson, Allan J Collins, Shu-Cheng Chen, Suying Li, Gabriel Chodick, Varda Shalev, Nachman Ash, Bracha Shainberg, Jack F M Wetzels, Peter J Blankestijn, Arjan D van Zuilen, Mark J Sarnak, Andrew S Levey, Lesley A Inker, Vandana Menon, Florian Kronenberg, Barbara Kollerits, Eberhard Ritz, Girish N Nadkarni, Erwin P Bottinger, Stephen B Ellis, Rajiv Nadukuru, Marc Froissart, Benedicte Stengel, Marie Metzger, Jean-Philippe Haymann, Pascal Houillier, Martin Flamant, C Raina Elley, Timothy Kenealy, Simon A Moyes, John F Collins, Paul L Drury, Kunitoshi Iseki, Amit X Garg, Eric McArthur, Gihad Nesrallah, S Joseph Kim, Robert G Nelson, William C Knowler, David G Warnock, Paul Muntner, Suzanne Judd, William McClellan, Orlando Gutierrez, Hiddo J Lambers Heerspink, Barry E Brenner, Dick de Zeeuw, Sun Ha Jee, Heejin Kimm, Yejin Mok, Marie Evans, Maria Stendahl, Navdeep Tangri, Maneesh Sud, David Naimark, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Josef Coresh, Ron T Gansevoort, Morgan E Grams, Paul E de Jong, Kunitoshi Iseki, Andrew S Levey, Kunihiro Matsushita, Mark J Sarnak, Benedicte Stengel, David Warnock, Mark Woodward, Shoshana H Ballew, Josef Coresh, Morgan E Grams, Kunihiro Matsushita, Yingying Sang, Mark Woodward

Abstract

Importance: Identifying patients at risk of chronic kidney disease (CKD) progression may facilitate more optimal nephrology care. Kidney failure risk equations, including such factors as age, sex, estimated glomerular filtration rate, and calcium and phosphate concentrations, were previously developed and validated in 2 Canadian cohorts. Validation in other regions and in CKD populations not under the care of a nephrologist is needed.

Objective: To evaluate the accuracy of the risk equations across different geographic regions and patient populations through individual participant data meta-analysis.

Data sources: Thirty-one cohorts, including 721,357 participants with CKD stages 3 to 5 in more than 30 countries spanning 4 continents, were studied. These cohorts collected data from 1982 through 2014.

Study selection: Cohorts participating in the CKD Prognosis Consortium with data on end-stage renal disease.

Data extraction and synthesis: Data were obtained and statistical analyses were performed between July 2012 and June 2015. Using the risk factors from the original risk equations, cohort-specific hazard ratios were estimated and combined using random-effects meta-analysis to form new pooled kidney failure risk equations. Original and pooled kidney failure risk equation performance was compared, and the need for regional calibration factors was assessed.

Main outcomes and measures: Kidney failure (treatment by dialysis or kidney transplant).

Results: During a median follow-up of 4 years of 721,357 participants with CKD, 23,829 cases kidney failure were observed. The original risk equations achieved excellent discrimination (ability to differentiate those who developed kidney failure from those who did not) across all cohorts (overall C statistic, 0.90; 95% CI, 0.89-0.92 at 2 years; C statistic at 5 years, 0.88; 95% CI, 0.86-0.90); discrimination in subgroups by age, race, and diabetes status was similar. There was no improvement with the pooled equations. Calibration (the difference between observed and predicted risk) was adequate in North American cohorts, but the original risk equations overestimated risk in some non-North American cohorts. Addition of a calibration factor that lowered the baseline risk by 32.9% at 2 years and 16.5% at 5 years improved the calibration in 12 of 15 and 10 of 13 non-North American cohorts at 2 and 5 years, respectively (P = .04 and P = .02).

Conclusions and relevance: Kidney failure risk equations developed in a Canadian population showed high discrimination and adequate calibration when validated in 31 multinational cohorts. However, in some regions the addition of a calibration factor may be necessary.

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Figures

Figure 1. Discrimination statistics (C statistics) for…
Figure 1. Discrimination statistics (C statistics) for original 4-variable equation at 2 and 5 years by cohort
An asterisk indicates this cohorts measuring dipstick proteinuria. Due to a limited number of events, confidence intervals were wide in some studies and therefore capped at 1.00 (maximum value for C statistic). Size is proportional to the weight of the study in a random effects meta-analysis. Arrows indicate that the true values are beyond the range of the axis. Representative references and expanded acronyms for each cohort name are provided in eAppendix 3.
Figure 2. Discrimination statistics (C statistics) for…
Figure 2. Discrimination statistics (C statistics) for original 4-variable and 8-variable equations at 2 and 5 years by subgroup
In the 4-variable equation analyses, 31 cohorts contributed for 2-year analysis and 26 cohorts for 5-year analysis. In the 8-variable equation analyses, 16 cohorts contributed for 2-year analysis and 11 cohorts contributed for 5-year analysis.
Figure 3. Refit baseline hazard of original…
Figure 3. Refit baseline hazard of original 4-variable equation at 2 and 5 years in individual cohorts stratified by region
Horizontal gray line represents the centered baseline hazard for the original 4-variable KFRE (age 70 years, male 56%, eGFR 36 ml/min/1.73 m2, ACR 170 mg/g); the red and green horizontal line represent the weighted mean refit baseline hazard within each region (North America and non-North America). NA: North America, NZ: New Zealand, E: Europe, I: Israel, A: Asia. The 25 cohorts included represent studies with available urine albumin-to-creatinine ratio. Studies with dipstick proteinuria were not included in the calculation. The North America cohorts include AASK, ARIC, BC CKD, CCF_ACR, CRIC, Geisinger, ICES-KDT, MDRD, Mt Sinai BioMe, Pima, REGARDS, Sunnybrook, and VA CKD. The New Zealand cohort is NZDCS. The Europe cohorts include CRIB, GCKD, GLOMMS-1, HUNT, MASTERPLAN, MMKD, Nephrotest, RENAAL, and SRR-CKD. The Israel cohort is Maccabi. The Asia cohort is Gonryo.

References

    1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7;298(17):2038–2047.
    1. O'Hare AM, Batten A, Burrows NR, et al. Trajectories of kidney function decline in the 2 years before initiation of long-term dialysis. Am J Kidney Dis. 2012 Apr;59(4):513–522.
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296–1305.
    1. O'Hare AM, Bertenthal D, Walter LC, et al. When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration? Kidney Int. 2007 Mar;71(6):555–561.
    1. Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098–1107.
    1. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011 Apr 20;305(15):1553–1559.
    1. Tonelli M, Manns B. Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time? JAMA. 2011 Apr 20;305(15):1593–1595.
    1. Drawz PE, Goswami P, Azem R, Babineau DC, Rahman M. A simple tool to predict end-stage renal disease within 1 year in elderly adults with advanced chronic kidney disease. J Am Geriatr Soc. 2013 May;61(5):762–768.
    1. Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, Blankestijn PJ, Wetzels JF. Validation of the kidney failure risk equation in European CKD patients. Nephrol Dial Transplant. 2013 Jul;28(7):1773–1779.
    1. Acedillo RR, Tangri N, Garg AX. The kidney failure risk equation: on the road to being clinically useful? Nephrol Dial Transplant. 2013 Jul;28(7):1623–1624.
    1. Marks A, Fluck N, Prescott GJ, et al. Looking to the future: predicting renal replacement outcomes in a large community cohort with chronic kidney disease. Nephrol Dial Transplant. 2015 Sep;30(9):1507–1517.
    1. Elley CR, Robinson T, Moyes SA, et al. Derivation and validation of a renal risk score for people with type 2 diabetes. Diabetes Care. 2013 Oct;36(10):3113–3120.
    1. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12;375(9731):2073–2081.
    1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–612.
    1. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941–1951.
    1. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clin Chem. 2007 Apr 1;53(4):766–772.
    1. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878.
    1. Grams ME, Li L, Greene TH, et al. Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK) Am J Kidney Dis. 2015 Mar;65(3):394–402.
    1. D'Agostino RB, Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001 Jul 11;286(2):180–187.
    1. Brier G. Verification of forecasts expressed in terms of probability. Monthly Weather Review. 1950;78:1–3.
    1. Kidney Disease Improving Global Outcomes (KDIGO) Work Group. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 5: Referral to specialists and models of care. Kidney International Supplements. 2013;3(1):112–119.
    1. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011 Jun;79(12):1331–1340.
    1. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011 Jun;79(12):1341–1352.
    1. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011 Jul;80(1):93–104.
    1. Hallan SI, Matsushita K, Sang Y, et al. Age and Association of Kidney Measures With Mortality and End-stage Renal Disease. JAMA. 2012 Oct 30;308(22):2349–2360.
    1. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649–1661.
    1. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380(9854):1662–1673.
    1. Nitsch D, Grams ME, Sang Y, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ. 2013;346:f324.
    1. Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013 Sep 5;369(10):932–943.
    1. Wen CP, Matsushita K, Coresh J, et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int. 2014 Oct;86(4):819–827.
    1. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014 Jun 25;311(24):2518–2531.
    1. Grams ME, Sang Y, Ballew SH, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Age, Race, and Sex With Acute Kidney Injury. Am J Kidney Dis. 2015 Oct;66(4):591–601.
    1. James MT, Grams ME, Woodward M, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015 Oct;66(4):602–612.
    1. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015 Jul;3(7):514–525.
    1. Grams ME, Sang Y, Levey AS, et al. Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. N Engl J Med. 2015 Nov 6;
    1. Tangri N, Kitsios GD, Inker LA, et al. Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med. 2013 Apr 16;158(8):596–603.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2013;3(1):1–150.
    1. Hemmelgarn BR, James MT, Manns BJ, et al. Rates of treated and untreated kidney failure in older vs younger adults. JAMA. 2012;307(23):2507–2515.
    1. Fried LF, Emanuele N, Zhang JH, et al. Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013 Nov 14;369(20):1892–1903.
    1. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492–2503.
    1. Turin TC, Tonelli M, Manns BJ, et al. Lifetime risk of ESRD. J Am Soc Nephrol. 2012 Sep;23(9):1569–1578.
    1. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15;305(23):2432–2439.

Source: PubMed

3
Tilaa